Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of isolated soybean protein in prevention or treatment of cardiotoxicity caused by anthracycline antineoplastic drug

A technology of isolated soybean protein and anti-tumor drugs, which is applied in drug combinations, hydrolyzed protein components, and cardiovascular system diseases. Effects of heart weight, ease of acceptance, and reduction of inflammatory infiltrates

Inactive Publication Date: 2018-01-19
河南省医药科学研究院
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Some scholars have found that polymer-drug conjugates can change the biodistribution of drugs, improve pharmacokinetics and pharmacodynamic properties, and have designed and synthesized pectin-doxorubicin conjugates and xyloglucan-doxorubicin However, the conjugates are expensive and have low drug loading, which affects the therapeutic effect on tumors
Currently, there is no effective and affordable prevention or treatment of these toxic side effects, and this situation urgently needs to change

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of isolated soybean protein in prevention or treatment of cardiotoxicity caused by anthracycline antineoplastic drug
  • Application of isolated soybean protein in prevention or treatment of cardiotoxicity caused by anthracycline antineoplastic drug
  • Application of isolated soybean protein in prevention or treatment of cardiotoxicity caused by anthracycline antineoplastic drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: Effect of Soybean Protein Isolate on Adriamycin Myocardial Injury in Mice

[0020] (1) Animal modeling

[0021] Fifty male Kunming mice of SPF grade, weighing 18-22 g, were selected and divided into 20 normal control groups (group A), 24 model groups (group B), and 26 soybean protein isolate groups (group C). Animals in groups A and B were fed with common feed; animals in group C were fed with soybean protein isolate (Hubei Yunmeng Longyun Protein Food Co., Ltd., batch number: 20120321-5) mixed with normal feed at a ratio of 1:5. Animals in group A were intraperitoneally injected with normal saline 0.09 ml / 10 g body weight, mice in groups B and C were intraperitoneally injected with 18 mg / kg (0.09 ml / 10 g body weight) of adriamycin (Zhejiang Hisun Pharmaceutical Co., Ltd., batch number 15006911 ), observed for 8 days.

[0022] (2) Index observation and detection methods

[0023] 1. Survival number and survival: After the start of the experiment, the number...

Embodiment 2

[0041] Example 2: Effects of Soybean Protein Isolate on Body Weight, Serum Modified Albumin and Total Sulfhydryl in Adriamycin Myocardial Injury Mice

[0042] (1) Animal modeling and group administration

[0043] Eighteen male Kunming mice, weighing 18-22 g, were randomly divided into three groups: normal control group (group A), intraperitoneally injected with normal saline (0.09 ml / 10 g body weight), and fed normally; model control group (group A) Group B) Adriamycin injection was injected intraperitoneally at a dose of 18 mg / kg (0.09 ml / 10 g body weight) and fed normally; Adriamycin injection was injected intraperitoneally, and fed with 20% high-protein feed.

[0044] (2) Observation indicators

[0045] The body weight changes of the mice in each group were recorded every day, and the serum was collected on the third day of the experiment to detect the levels of total sulfhydryl groups and ischemic modified albumin.

[0046] (3) Experimental results

[0047] 1. Weight c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of isolated soybean protein in prevention or treatment of cardiotoxicity caused by an anthracycline antineoplastic drug and is intended to solve the problem that ananthracycline medicine easily produces toxic and side effects in an organism during malignant tumor treatment. The isolated soybean protein is extracted from natural plants and has the characteristics of good safety and environmental friendliness. In an animal experiment, the survival rate of animals can be effectively improved, heart weight can be effectively improved, cardiac muscle fiber breakage can be effectively reduced, inflammatory infiltration is alleviated, ischemia modified albumin level in mouse serum can be effectively lowered, and the total sulfhydryl level of the mouse serum can be effectively improved. The isolated soybean protein is low in cost and beneficial to clinical popularization and application and provides a new thought and new solution for a method used for treating the cardiotoxicity caused by the anthracycline antineoplastic drug.

Description

technical field [0001] The invention relates to the technical field of prevention and treatment of drug toxicity, in particular to the application of a soybean protein isolate in the prevention or treatment of myocardial toxicity caused by anthracycline antitumor drugs. Background technique [0002] Anthracyclines include adriamycin, daunorubicin, aclarubicin, epirubicin, pirarubicin, idarubicin, and mitoxantrone, among which adriamycin (ADR) is One of the broad-spectrum anti-tumor drugs commonly used clinically has achieved good curative effect in the treatment of malignant tumors, and is widely used in the treatment of solid tumors, leukemia, lymphoma, breast cancer and other tumors. This type of drug has a high affinity to myocardial tissue, and will produce cumulative and dose-dependent myocardial toxicity, which will further develop into irreversible myocardial damage, and eventually lead to congestive heart failure, and the resulting cardiotoxicity may appear after med...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/01A61P9/00
Inventor 何美霞贺石林刘琼朱建立郭佳盛誉妍姜山朱奎成李志刚郭龙辉何凤霞张莉蓉
Owner 河南省医药科学研究院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com